Stifel Financial’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.13M | Buy |
60,539
+10,159
| +20% | +$517K | ﹤0.01% | 1641 |
|
|
2025
Q4 | $2.5M | Sell |
50,380
-12,375
| -20% | -$602K | ﹤0.01% | 1776 |
|
|
2025
Q3 | $3M | Sell |
62,755
-839
| -1% | -$33.8K | ﹤0.01% | 1607 |
|
|
2025
Q2 | $2M | Sell |
63,594
-8,090
| -11% | -$259K | ﹤0.01% | 1851 |
|
|
2025
Q1 | $2.35M | Buy |
71,684
+3,721
| +5% | +$132K | ﹤0.01% | 1649 |
|
|
2024
Q4 | $2.46M | Sell |
67,963
-1,171
| -2% | -$41.2K | ﹤0.01% | 1635 |
|
|
2024
Q3 | $2.16M | Buy |
69,134
+1,093
| +2% | +$34.1K | ﹤0.01% | 1717 |
|
|
2024
Q2 | $1.82M | Sell |
68,041
-1,274
| -2% | -$36.9K | ﹤0.01% | 1782 |
|
|
2024
Q1 | $2.36M | Buy |
69,315
+14,862
| +27% | +$442K | ﹤0.01% | 1599 |
|
|
2023
Q4 | $1.58M | Buy |
54,453
+3,373
| +7% | +$89.4K | ﹤0.01% | 1829 |
|
|
2023
Q3 | $1.41M | Buy |
51,080
+9,890
| +24% | +$301K | ﹤0.01% | 1823 |
|
|
2023
Q2 | $1.24M | Buy |
41,190
+4,764
| +13% | +$167K | ﹤0.01% | 1939 |
|
|
2023
Q1 | $1.32M | Buy |
36,426
+101
| +0.3% | +$3.88K | ﹤0.01% | 1849 |
|
|
2022
Q4 | $1.3M | Buy |
36,325
+1,979
| +6% | +$68.8K | ﹤0.01% | 1810 |
|
|
2022
Q3 | $1.16M | Buy |
34,346
+3,134
| +10% | +$102K | ﹤0.01% | 1866 |
|
|
2022
Q2 | $903K | Buy |
31,212
+3,829
| +14% | +$110K | ﹤0.01% | 2079 |
|
|
2022
Q1 | $885K | Buy |
27,383
+1,504
| +6% | +$46.1K | ﹤0.01% | 2203 |
|
|
2021
Q4 | $755K | Buy |
25,879
+2,794
| +12% | +$84.8K | ﹤0.01% | 2323 |
|
|
2021
Q3 | $616K | Buy |
23,085
+5,734
| +33% | +$154K | ﹤0.01% | 2452 |
|
|
2021
Q2 | $534K | Buy |
17,351
+2,761
| +19% | +$84.6K | ﹤0.01% | 2546 |
|
|
2021
Q1 | $382K | Buy |
14,590
+1,883
| +15% | +$52.7K | ﹤0.01% | 2653 |
|
|
2020
Q4 | $320K | Buy |
12,707
+1,296
| +11% | +$27.9K | ﹤0.01% | 2561 |
|
|
2020
Q3 | $238K | Buy |
11,411
+449
| +4% | +$10.2K | ﹤0.01% | 2526 |
|
|
2020
Q2 | $260K | Sell |
10,962
-1,731
| -14% | -$38.2K | ﹤0.01% | 2441 |
|
|
2020
Q1 | $234K | Sell |
12,693
-7,349
| -37% | -$154K | ﹤0.01% | 2349 |
|
|
2019
Q4 | $468K | Sell |
20,042
-19,328
| -49% | -$469K | ﹤0.01% | 2301 |
|
|
2019
Q3 | $1.07M | Sell |
39,370
-23,131
| -37% | -$685K | ﹤0.01% | 1704 |
|
|
2019
Q2 | $2.06M | Buy |
62,501
+27,962
| +81% | +$958K | 0.01% | 1309 |
|
|
2019
Q1 | $1.21M | Buy |
34,539
+2,981
| +9% | +$111K | ﹤0.01% | 1534 |
|
|
2018
Q4 | $1.04M | Sell |
31,558
-1,135
| -3% | -$48.8K | ﹤0.01% | 1493 |
|
|
2018
Q3 | $1.65M | Sell |
32,693
-6,187
| -16% | -$306K | ﹤0.01% | 1374 |
|
|
2018
Q2 | $2.33M | Sell |
38,880
-2,381
| -6% | -$123K | 0.01% | 1125 |
|
|
2018
Q1 | $1.9M | Sell |
41,261
-4,918
| -11% | -$205K | 0.01% | 1192 |
|
|
2017
Q4 | $1.84M | Buy |
46,179
+604
| +1% | +$23.9K | 0.01% | 1184 |
|
|
2017
Q3 | $1.82M | Sell |
45,575
-2,930
| -6% | -$127K | 0.01% | 1171 |
|
|
2017
Q2 | $2.09M | Sell |
48,505
-2,796
| -5% | -$99.5K | 0.01% | 1079 |
|
|
2017
Q1 | $1.61M | Buy |
51,301
+831
| +2% | +$22.3K | 0.01% | 1186 |
|
|
2016
Q4 | $1.28M | Buy |
50,470
+17,770
| +54% | +$397K | 0.01% | 1257 |
|
|
2016
Q3 | $814K | Sell |
32,700
-5,807
| -15% | -$131K | ﹤0.01% | 1452 |
|
|
2016
Q2 | $785K | Sell |
38,507
-73,703
| -66% | -$1.31M | ﹤0.01% | 1500 |
|
|
2016
Q1 | $1.71M | Sell |
112,210
-15,918
| -12% | -$208K | 0.01% | 984 |
|
|
2015
Q4 | $1.72M | Buy |
128,128
+14,360
| +13% | +$222K | 0.01% | 1034 |
|
|
2015
Q3 | $1.6M | Sell |
113,768
-4,097
| -3% | -$76.2K | 0.01% | 1018 |
|
|
2015
Q2 | $2M | Buy |
117,865
+8,533
| +8% | +$121K | 0.01% | 993 |
|
|
2015
Q1 | $1.32M | Buy |
109,332
+72,827
| +199% | +$688K | 0.01% | 1151 |
|
|
2014
Q4 | $303K | Buy |
36,505
+250
| +0.7% | +$2.1K | ﹤0.01% | 1876 |
|
|
2014
Q3 | $315K | Buy |
36,255
+9,450
| +35% | +$85.4K | ﹤0.01% | 1773 |
|
|
2014
Q2 | $294K | Buy |
26,805
+2,200
| +9% | +$19.6K | ﹤0.01% | 1790 |
|
|
2014
Q1 | $220K | Buy |
+24,605
| New | +$227K | ﹤0.01% | 1881 |
|
Other funds holding SUPN
VPM
VCM
NAMI
AC
Stifel Financial's SUPN Position: Q1 2026 in Review
Stifel Financial increased its Supernus Pharmaceuticals (SUPN) stake by 20% in Q1 2026, buying an estimated $517K and bringing the position to 60,539 shares worth $3.13M. The position accounts for ﹤0.01% of the portfolio, ranked #1641.
Stifel Financial first reported a position in SUPN in Q1 2014 and has held it in 49 quarters since. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- Stifel Financial held 60,539 shares of Supernus Pharmaceuticals worth $3.13M as of Q1 2026.
- Stifel Financial bought 10,159 Supernus Pharmaceuticals shares in Q1 2026, an estimated $517K.
- Supernus Pharmaceuticals made up ﹤0.01% of Stifel Financial's portfolio in Q1 2026, its #1641 holding.
- Stifel Financial first reported a position in Supernus Pharmaceuticals in Q1 2014 and has held it in 49 quarters since.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on Stifel Financial's 13F filing for Q1 2026, filed 12 May 2026.